

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 February 2025 (27.02.2025)



(10) International Publication Number
WO 2025/040767 A1

(51) International Patent Classification:
C07D 487/08 (2006.01) *A61P 35/00* (2006.01)
A61K 31/4995 (2006.01)

(21) International Application Number:
PCT/EP2024/073621

(22) International Filing Date:
22 August 2024 (22.08.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
23315323.8 22 August 2023 (22.08.2023) EP
24315092.7 14 March 2024 (14.03.2024) EP

(71) Applicant: **SANOFI** [FR/FR]; 46 Avenue de la Grande Armée, 75017 Paris (FR).

(72) Inventors: **AHLSTEN, Nanna**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **ALEKSIC, Stevan**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **DE LAS HERAS RUIZ, Edgar**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **KHOR, Someina**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **LECCI, Cristina**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **RONAN, Baptiste**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **PÉREZ, Victor Sebastián**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **BARBEAU, Olivier**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **FOSTER, Holly**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR).

(74) Agent: **MATHYS & SQUIRE**; The Shard, 32 London Bridge Street, London SE1 9SG (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— with international search report (Art. 21(3))

(54) Title: 2-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-1,3,5-TRIAZINE DERIVATIVES AS KRAS G12D INHIBITORS FOR THE TREATMENT OF CANCER

(57) Abstract: Compounds are provided which can inhibit KRAS G12D. Also provided are pharmaceutical compositions and medical uses of the same, including the use in treating or preventing conditions such as cancers.

WO 2025/040767 A1